Samsung nets FDA clearance
Samsung nets FDA clearanceKorean PACS vendor Samsung has officially entered the U.S. market, with news that its Raypax PACS product line has received Food and Drug Administration 510(k) clearance. Raypax is based on Windows NT and Windows 98
Samsung nets FDA clearance
Korean PACS vendor Samsung has officially entered the U.S. market, with news that its Raypax PACS product line has received Food and Drug Administration 510(k) clearance. Raypax is based on Windows NT and Windows 98 architecture, although its image server is also available on the Unix platform (
PNN
9/98).
Raypax comprises display software, an image server, a Web server, a film and plain paper printer server, modality interfaces, and a Web-based teleradiology system. Digitizers as well as DICOM and HL7 gateways are available. Samsung also markets a radiology information system.
Samsung, which has U.S. operations in San Jose, CA, plans to install a U.S. beta site for Raypax this month. Raypax is sold through distributors, and Asian sales of Raypax began in April. Beta testing of Raypax was performed at Samsung Medical Center in Seoul.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
